NCT06456580Phase 3Recruiting

A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2027-05Estimated

Enrollment · participants180Estimated

Source updated2026-06-18Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-02-17 · 1 field changed

Primary completion date changed

− Before

~~Dec 2026~~

+ After

May 2027

Check registry source

Posted 2026-01-27 · 1 field changed

Primary completion date changed

− Before

~~Jul 2026~~

+ After

Dec 2026

Check registry source

Study details

Conditions studied

Generalized Myasthenia Gravis

Treatments or interventions studied

TelitaciceptBiologicalAlso known as RC18, RC18-L
PlaceboDrug

Primary outcomes · main study measures

Read the study measures

measure: Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) score at Week 24; description: The MG-ADL is an 8-item patient-reported outcome measure assessing MG symptoms and their effects on daily activities. Each item in the scale is scored on a 0 to 3 (0=normal, 3=severe disease) point scale. The total score is the sum of all individual item scores ranging from 0 to 24. Higher scores indicate more severe disability due to MG. A decrease from Baseline score indicates improvement.; timeFrame: Week 24

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history